Kornimate/medical-research-clean huggingface dataset:
the effect of prolotherapy in the care process of pressure injuries

Conditions: Pressure Ulcer

Summary: the goal of this \[type of study: randomized controlled clinical trial\] is to \[determining the effect of prolotherapy use on the wound care process\]. the main question it aims to answer is: • \[the use of proliferative substances in the care of 1st, 2nd and 3rd stage pressure injuries has a positive effect on the wound healing period\]. participants will \[in patients with pressure injuries, wound irrigation with saline and wound irrigation with gelofusin were applied\]. researchers will compare \[depth, length and width of the wound\].

in the study, wound irrigation with saline and wound irrigation with gelofusin will be applied to patients with pressure injuries. cleaning of the wound can be done with gases moistened with saline, or irrigation method can be applied with the help of an injector. sufficient pressure can be provided with an 18g needle attached injector. irrigation with 50-100cc saline per square centimeter is recommended. in the experimental group, the wound will be washed with gelofusine as prolotherapy, and the wound will be closed with sterile sponge and fixative tape. in the control group, the wound will be covered with sterile sponge and fixative tape by washing with physiological saline. this process will be repeated 2 times a day and will be repeated and observed for 3 days in line with the literature. in this study, while the wound is irrigated, the solution will first be drawn into a 50 cc syringe and prepared. a protective cover will be used to prevent the sterile sponge, fixation tape, gloves and solution required for dressing from contaminating the patient bed. the patient will be given an appropriate position according to the location of the wound. the needle of the syringe containing the solution will be removed and kept at a distance of 3 cm from the wound area, and the solution will be slowly poured over the entire wound. when the irrigation process is finished, the wound area will be dried and the wound will be closed with sterile sponge.

Eligibility criteria:
inclusion criteria: * patients with 1st, 2nd and 3rd stage pressure injuries * patients over 18 years of age * patients who volunteered to participate in the study exclusion criteria: * patients without 1st, 2nd and 3rd stage pressure injuries * patients under 18 years of age * patients who did not volunteer to participate in the study * patients allergic to gelofusin solution

Keywords: pressure injury proliferative wound care
bronchial inflammation in patients with severe immune deficiency under immunoglobulin treatment

Conditions: Immune Deficiency

Summary: the purpose of the clinical trial is to gain a more substantial understanding of bronchial inflammation in patients with severe primary immundeficiency under immunoglobulin therapy. it is intended to characterize the systemical such as the bronchial inflammation (il-1, il-2, il-6, il-8, il-17, tnf-a, nfkb, ifn-gamma, tgf-beta, tlr2 und tlr4)in children with severe immune deficiency in order to generate new treatment strategies based on the results. the methods being used for characterization purposes within this trial include specific lung function tests ( spirography, bodyplethysmographie w. helium) such as the analysis of eno and eco. furthermore, sputum and serum samples are being analyzed by quantitative real-time polymerase chain reaction (pcr),(qrt-pcr) and by cytometric bead assay (cba). components of the innate immune system (mannose-binding protein, tlr recognition proteins and surfactant proteins) are genetically determined from sputum or blood respectively. in the conduct of the study the investigators will retrospectively and systematically evaluate the available high-resolution computed tomography (hrct) studies of affected patients.

the clinical trial contains a patient collective of 50 (6-60 years of age) that shall be eventually compared to a control group equal in age and gender. both the patients and the healthy subjects are recruited from the outpatient clinic of pediatric allergy and pulmonology. methods and work programme: this study consists of two study visits (v1 and v2) v1: * measurement of nitric oxide in expired air (eno) * measurement of carbon monoxide in the exhaled air (eco) * lung function testing with spirography and bodyplethysmographie * blood test: blood count, crp, rast, serum inflammatory mediators, genetic markers of the non-specific pulmonary defense system * induced sputum for inflammatory mediators and microbiological investigations v2: \*unspecific bronchial provocation test with methacholine (pd20 fev1 metacholine)

Eligibility criteria:
inclusion criteria: * informed consent * 6 to 60 years of age * known severe immune deficiency under immunoglobulin therapy/ no immune deficiency ( depending on study group) * ability to perform lung function tests and inhalation exclusion criteria: * \ 60 years of age on the day of written informed consent * acute illness with systemic or bronchial inflammation * every chronic condition or infection (e.g. hiv, tuberculosis, malignancy) * pregnancy * known alcohol and/ or drug abuse * inability to understand the extent and scope of the study

Keywords: severe primary immune deficieny
re-establishing flow via drug coated balloon for the treatment of urethral stricture disease

Conditions: Urethral Stricture

Summary: the study described below is designed to assess the safety and device performance for the drug coated balloon (dcb) for the treatment of urethral stricture.


Eligibility criteria:
inclusion criteria: 1. male subjects ≥ 18 years' old 2. visual confirmation of stricture via cystoscopy or urethrogram 3. single lesion anterior urethral stricture less than or equal to 3 cm 4. two (2) or more prior diagnosis and treatment of stricture treatments (including self-catheterization) including dviu (direct visual internal urethrotomy), but no prior urethroplasty 5. significant symptoms of stricture such as frequency of urination, dysuria, urgency, hematuria, slow flow, feeling of incomplete emptying, recurrent uti's (urinary tract infections). 6. ipss (international prostate symptom score) score of 13 or higher 7. lumen diameter \<12f by urethrogram 8. able to complete validated questionnaire independently 9. qmax \<12 ml/sec 10. guidewire must be able to cross the lesion exclusion criteria: 1. strictures greater than 3.0 cm long. 2. subjects that have more than 1 stricture. 3. sensitivity to paclitaxel or on medication that may have negative interaction with paclitaxel 4. subjects who have a suprapubic catheter 5. previous urethroplasty within the anterior urethra 6. stricture due to bacterial urethritis or untreated gonorrhea 7. stricture dilated or incised within the last 3 months 8. history of over active bladder or stress incontinence 9. previous radical prostatectomy 10. previous pelvic radiation 11. diagnosed kidney, bladder, urethral or ureteral stones or active stone passage in the past 6 months. 12. presence of a penile implant, artificial urinary sphincter, or stent(s) in the urethra or prostate 13. known neurogenic bladder, sphincter abnormalities, or poor detrusor muscle function

Keywords: early feasibility non-randomized
nephrodiab2 prospective randomized controlled open-labelled trial comparing effect of two haemoglobin levels

Conditions: Chronic Kidney Disease

Summary: in type 2 diabetics, progression from chronic kidney disease to end stage renal disease may be slowed down by therapeutic interventions as angiotensin converting enzyme inhibitors use, control of high blood pressure and proteinuria, control of hyperglycaemia, protein intake restriction, smoking cessation. correcting anaemia in these patients may prevent impairment of renal function. international guidelines indicate that haemoglobin level has to be of 110 g/l in these patients. we conduct an interventional randomized trial to evaluate the potential benefit of an haemoglobin level of 130 g/l in patients with type 2 diabetes and with a chronic kidney disease defined by a cockcroft's creatinine clearance of 25 - 60 ml/min.


Eligibility criteria:
inclusion criteria: type 2 diabetes. age between 18 and 80 years, male or female. cockcroft's clearance between 25 and 60 ml / min. haemoglobin level superior to 100 g/l and strictly inferior to 130 g/l exclusion criteria: malignancy solid organ transplant acute pathology in the two months before inclusion date myocardial infarction, stroke, pulmonary embolism in the six months before inclusion date contra-indication to martial treatment or epo treatment present inclusion in another clinical study patient who cannot answer questions of sf36 questionnaire

Keywords: anaemia chronic kidney disease type 2 diabetes randomized trial
imaging location of hamstring muscle lesions in sport and relationships with injury mechanism.

Conditions: Sport Injury; Hamstring Muscle Lesions

Summary: hamstring muscle injuries are a common pathology in sports mainly present in sprint and acceleration sports, accounting for about 12% of all football injuries. because of their frequency, risk of reinjury and financial cost, they can be considered as a public health problem. improving knowledge of the pathophysiology of hamstring muscle injury appears to be a relevant research focus for prevention purposes.

this study is a cohort of athletes in the context of suspicion of hamstring muscle injuries.

Eligibility criteria:
inclusion criteria: * to be recreational sportsmen, competitions, amateurs, high-level or professional * aged 18 to 50 years * perform an magnetic resonance imaging (mri) or an ultrasound of the thigh in the context of the suspicion of an acute hamstring muscle injury * injury during sport since less 21 days old. exclusion criteria: * a history of surgery of the anterior cruciate ligament with removal of the transplant in the posterior compartment of the thigh * an antecedent of surgery of the thigh. * inability to understand the french language for completing the self-questionnaire

Keywords: magnetic resonance imaging (mri) ultrasound sport hamstring muscle injury
the impact of lbbap vs rvp on the incidence of new-onset atrial fibrillation in patients with atrioventricular block

Conditions: Left Bundle Branch Area Pacing; Right Ventricular Pacing; Atrioventricular Block; Atrial Fibrillation

Summary: this is a single-center, randomized controlled study. the aim of this study is to compare the impact of left bundle branch area pacing versus traditional right ventricular pacing on the incidence of atrial fibrillation in patients with atrioventricular block.


Eligibility criteria:
inclusion criteria: * adult patients aged 18-85; * av block patients with ventricular pacing indications and the expected rate of ventricular pacing(vp)\> 40%, including (a) third-degree av block; (b) second degree av block (type ii); (c) intermittent advanced av block with expected vp\>40%; (d) symptomatic first degree av block and pr interval on ecg \> 300ms; * signed informed consent; exclusion criteria: * baseline echocardiographic assessment of patients with impaired lv function (lvef\<50%); * patients with the history of atrial fibrillation; * having difficulties in follow-up: those who cannot accept 2-year follow-up on time due to physical condition or other reasons; * pacemaker replacement without new implanted ventricular electrodes; * surgery is required within 1 year due to severe structural heart disease; * patients with tricuspid mechanical valve replacement, or congenital heart disease (including transposition of the great arteries, or permanent left superior vena cava, etc); * av block resulting from: (a) hypertrophic cardiomyopathy(hcm), (b) ventricular septal defect repair, and those who are unlikely to achieve successful lbbap procedure.
a study of optical imaging with light from radiotracers in cancer patients

Conditions: Thyroid Cancer

Summary: the purpose of this study is to test cerenkov luminescence imaging, which is a different way to take pictures of thyroid cancer and/or any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region.


Eligibility criteria:
inclusion criteria: * participant is 18 years of age or old * participant must meet one of the following: * patients with thyroid cancer scheduled for thyroid ablation therapy with 131i * patients with any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region who are scheduled to receive a clinical fdg pet/ct scan * patients with metastatic prostate cancer who are schedule for xofigo therapy with 223ra * patients scheduled to receive a standard of care 66ga-dota-tate or \[18f\]-parpi pet scan in the nuclear medicine clinic * patient undergoing lu-dota tate treatment in the nuclear medicine clinic exclusion criteria: * patients imaged for cerenkov luminescence are going to be required to be in a darkened enclosure for at least 10 minutes and sit still during image acquisition. any conditions that would prevent this will exclude the patients. this includes patients who unable to sit in a dark environment, have claustrophobic, inability to sit still for a few minutes * any other past medical, physiological or demographic concerns. this includes any patients with skin blemishes that are present at the dermis over the tumor, as these are of particular interest for use of this technique. this also includes open wounds on the area of interest.

Keywords: nodal metastases 17-538 memorial sloan kettering cancer center
high flow nasal cannula after esophagectomy

Conditions: Esophageal Cancer; Postoperative Pulmonary Atelectasis; Postoperative Pneumonia; Postoperative Pneumothorax; Postoperative Infection of Incision; Postoperative Acute Myocardial Infarction

Summary: this study will compare the effect of hfnc versus standard oxygen administration after elective esophagectomy for cancer.


Eligibility criteria:
inclusion criteria: * elective esophagectomy for cancer * mets≥4 * age 18-85 * written informed consent exclusion criteria: * asa\>3 * copd≥ iii stage according to gold criteria * fev1\<50% * ef\<30% * nyha\>2 * bmi\ 35 kg/m2 * ckd with egfr\<60 ml/min

Keywords: esophageal cancer anesthesia high flow nasal cannula pneumonia esophagectomy acute myocardial infarction
nlp-based feedback to improve risk comms and informed shared decision making

Conditions: Prostate Cancer

Summary: in this pilot study, the investigators will show feasibility of the nlp-based feedback system in 20 consultations of men with newly diagnosed prostate cancer. the investigators will recruit from the practices of up to 10 physicians who typically see these patients. the investigators will report the top five sentences from each consultation across key content areas (cancer prognosis, life expectancy, erectile dysfunction, urinary incontinence, and irritative urinary symptoms) to both patients and physicians within 2 weeks of the consultation.

the primary research procedures are: 1. audio recording and transcribing treatment counseling discussions for 20 men with newly diagnosed clinically localized prostate cancers and utilize nlp to extract key content using the system described above. 2. reports including the top five sentences by nlp probability for key content areas will be generated and will be provided to patients and providers within 2 weeks after each case. 3. for patients, decisional conflict and risk perception will be assessed before and after receiving the nlp-based feedback. 4. for physicians, the investigators will assess baseline quality of risk communication, any changes in individual physician communication over time, and accuracy of risk estimates for key content areas. 5. within 2 weeks of receiving the nlp-based feedback, the investigators will conduct a 30-minute semi-structured interview with patients to obtain their opinions on the utility and ideal implementation strategy for the nlp-based feedback. 6. at the conclusion of the pilot trial, the investigators will conduct 30-minute semi-structured interview with counseling physicians to obtain their opinions on the utility and ideal implementation strategy for the nlp-based feedback.

Eligibility criteria:
inclusion criteria: 1. men undergoing initial treatment consultation for clinically localized prostate cancer; 2. men with upgraded prostate cancer on active surveillance considering conversion to definitive local therapy. 3. cedars-sinai patient. 4. ability to read and write in english. exclusion criteria: 1. under 18 years of age; 2. subjects with difficulty communicating or dementia; 3. non-english speakers, given that our nlp-based tools cannot be used with languages other than english; 4. men with locally advanced or metastatic prostate cancer; 5. men who have already been treated for clinically localized prostate cancer

Keywords: prostate cancer consultation review feedback natural process
a phase 2a trial of epi-743 for patients with parkinson's disease

Conditions: Parkinson's Disease

Summary: the purpose of this study is to evaluate the effects of epi-743 in patients with parkinson's disease.


Eligibility criteria:
inclusion criteria: 1. diagnosis of parkinson's disease 2. age 40 - 75 3. ambulatory with or without assistance 4. hoehn and yahr scale score of 1 - 3 5. patient able to consent and comply with protocol requirements 6. abstention from use of coenzyme q10, vitamin e, azilect and idebenone two weeks prior to enrollment and during course of treatment with epi-743 exclusion criteria: 1. allergy to epi-743 or sesame oil 2. allergy to vitamin e 3. clinical history of bleeding or abnormal baseline pt/ptt 4. diagnosis of any other neurologic disease 5. malignancy within past two years 6. pregnant or plans to become pregnant 7. concomitant ophthalmologic disease 8. history of stroke 9. history of brain surgery 10. inability to undergo mri scan or mrs 11. hepatic insufficiency with lfts greater than two times upper limit of normal 12. renal insufficiency requiring dialysis 13. end stage cardiac failure 14. fat malabsorption syndromes precluding drug absorption 15. use of anticoagulant medications, azilect
study of a predictor for cervix cancer

Conditions: Cervix Cancer; Oncology

Summary: non operated cervix cancer are usually treated by radio-chemotherapy. non control local rate is inexplicably close to 30%. however, important volume of those tumors and their hypoxia degree induce phenomenon of pathologic angiogenesis, explaining these therapeutic failures. persistence of tumor hypoxia could be a predictive factor of local control

hpv linked cervix cancer is the second most prevalent form of female cancer. it's also the leading cause of death by cancer in asia, south america and africa. hopefully, screening program lead to a 50 % of mortality reduction during the past 40 years. classic therapeutic strategy consists of external pelvic radiation therapy associated with chemotherapy and followed by brachytherapy. curative surgical removal is realized 4 to 6 weeks after radiation therapy. however relapse rate is frequent (20 to 30%). biological mechanisms involved in this high relapse rate are not understood. nevertheless, it is suggest that initial hypoxia of cervix tumor during 20 gy radiation therapy is a pejorative prognostic factor. at the opposite, the amelioration of tumor vascularisation during 20 gy radiation therapy is a positive prognostic factor. it's possible that an amelioration of hypoxia lead to lesser tumor resistance to radiotherapy. however such possibility has to be test during clinical trial. thus, the objective of anoxicol study is to evaluate the predictive value of persistent hypoxia, during 20 gy radiation therapy associated with chemotherapy, for local control of cervix cancer.

Eligibility criteria:
inclusion criteria: * cervix epidermoid cancer or adenocarcinoma : i to iiib * treatment by radiochemotherapy * ecog ≤ 1 * social and psychological compliance for standard treatment of radiochemotherapy for cervix carcinoma * patient affiliated to health insurance system * signed informed consent exclusion criteria : * contraindication to chemoradiotherapy * resequable cervical cancer * para-aortic metastases histologically proven * inability to perform an abdominal mri or a pet scan * contraindications related to mri: pacemaker, vascular clip, and all devices incompatible with the electromagnetic field generated by mri * unbalanced diabete * administration of epo * transfusion within 3 days before the first biopsy * creatinine clearance under 60 ml / min; * anc \<1500 / mm3 and platelets \<120,000 / mm3 * neuropathy, diabetes (fasting glucose greater than 140 mg / l) or any other condition that strongly contraindicates concomitant chemotherapy with radiotherapy * sigmoid diverticulitis, crohn's disease or systemic disease, collagenose
respimer® netiflow® vs. saline solutions during nasal irrigation following bilateral ethmoidectomy (nasal polyposis)

Conditions: Polyp of Ethmoidal Sinus; Surgery

Summary: the main objective of this study is to compare the effects of respimer® netiflow® solution and device versus saline solution (0.9% nacl), the standard treatment, used with respimer® netiflow® device, both used postoperative care, in the context of ethmoid sinus surgery, at 14 days post-surgery.

this is a comparative study between two postoperative treatments following ethmoid sinus surgery. the purpose of this study is to compare the effect of respimer® netiflow® solution on nasal tissue repair versus saline solution (0.9% nacl), the standard treatment. the type of surgery selected for this study is total endoscopic ethmoidectomy. this is a frequently used standard surgery that requires nasal cleansing for an average of 28 days. this process allows the regeneration of the nasal epithelial lining of the wound (areas of exposed bone), as well as the healing of swelling and scarring due to the surgery. the follow up last 28 days with 4 visits (d7, d14, d21 and d28). respimer® netiflow® : device of class i, with ce mark, in the indication of sinus postoperative care.

Eligibility criteria:
inclusion criteria: * males or females between 18 and 65 years of age * subject in need of sinus surgery as bilateral total ethmoidectomy using an endoscopic endonasal approach whose pathology is the result of a: * sinonasal polyposis alone * sinonasal polyposis associated with asthma and / or intolerance to nsaids * free and informed written consent * member or beneficiary of a social security program exclusion criteria: * oral corticosteroid treatment since less than 2 months * premenopausal women not using effective contraception (oral or intrauterine device) * pregnant or nursing women * uncontrolled diabetes (not treated or stabilized by treatment) * hiv-positive status * autoimmune diseases affecting the nose and/or sinuses, immune dysfunctions (wegener's granulomatosis, churg-strauss syndrome, common variable immunodeficiency, sarcoidosis...), or malignant diseases (unclear histology) * all contraindication of respimer® netiflow® * all diseases resulting in difficulty coughing or swallowing * ongoing or past radiation treatment to the head and neck * ongoing or recent chemotherapy (within a three-month period) * subjects using anticoagulants * subjects taking part in another study that includes an exclusion period coinciding with that of the run-in period of this study * subjects placed under judicial protection * subjects who suffer from severe physical or psychological problems and whose condition can, according to the investigator, affect compliance with the study

Keywords: saline solution, isotonic / administration & dosage therapeutic irrigation / methods postoperative care / methods quality of life